Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Different levels of immunogenicity of two strains of Fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies.

Cottingham MG, van Maurik A, Zago M, Newton AT, Anderson RJ, Howard MK, Schneider J, Skinner MA.

Clin Vaccine Immunol. 2006 Jul;13(7):747-57.

2.

Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.

Bridge SH, Sharpe SA, Dennis MJ, Dowall SD, Getty B, Anson DS, Skinner MA, Stewart JP, Blanchard TJ.

Virol J. 2011 Sep 7;8:429. doi: 10.1186/1743-422X-8-429.

3.

Enhanced CD8+ T cell immune responses and protection elicited against Plasmodium berghei malaria by prime boost immunization regimens using a novel attenuated fowlpox virus.

Anderson RJ, Hannan CM, Gilbert SC, Laidlaw SM, Sheu EG, Korten S, Sinden R, Butcher GA, Skinner MA, Hill AV.

J Immunol. 2004 Mar 1;172(5):3094-100.

4.

Generation and immunogenicity of novel HIV/AIDS vaccine candidates targeting HIV-1 Env/Gag-Pol-Nef antigens of clade C.

Gómez CE, Nájera JL, Jiménez V, Bieler K, Wild J, Kostic L, Heidari S, Chen M, Frachette MJ, Pantaleo G, Wolf H, Liljeström P, Wagner R, Esteban M.

Vaccine. 2007 Mar 1;25(11):1969-92. Epub 2006 Dec 6.

PMID:
17224219
5.

Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers.

Vuola JM, Keating S, Webster DP, Berthoud T, Dunachie S, Gilbert SC, Hill AV.

J Immunol. 2005 Jan 1;174(1):449-55.

6.

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

Webster DP, Dunachie S, Vuola JM, Berthoud T, Keating S, Laidlaw SM, McConkey SJ, Poulton I, Andrews L, Andersen RF, Bejon P, Butcher G, Sinden R, Skinner MA, Gilbert SC, Hill AV.

Proc Natl Acad Sci U S A. 2005 Mar 29;102(13):4836-41. Epub 2005 Mar 21.

7.

Prime-boost immunization with DNA, recombinant fowlpox virus and VLP(SHIV) elicit both neutralizing antibodies and IFNgamma-producing T cells against the HIV-envelope protein in mice that control env-bearing tumour cells.

Radaelli A, Bonduelle O, Beggio P, Mahe B, Pozzi E, Elli V, Paganini M, Zanotto C, De Giuli Morghen C, Combadière B.

Vaccine. 2007 Mar 1;25(11):2128-38. Epub 2006 Nov 16.

PMID:
17241705
8.

A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.

Prieur E, Gilbert SC, Schneider J, Moore AC, Sheu EG, Goonetilleke N, Robson KJ, Hill AV.

Proc Natl Acad Sci U S A. 2004 Jan 6;101(1):290-5. Epub 2003 Dec 23.

9.

Expression and immunogenicity of sequence-modified human immunodeficiency virus type 1 subtype B pol and gagpol DNA vaccines.

zur Megede J, Otten GR, Doe B, Liu H, Leung L, Ulmer JB, Donnelly JJ, Barnett SW.

J Virol. 2003 Jun;77(11):6197-207.

10.

Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques.

De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, Ramshaw IA, Coupar BE, Boyle DB, Venturi V, Davenport MP, Kent SJ.

J Virol. 2007 Jan;81(1):292-300. Epub 2006 Oct 18.

11.

Immunogenicity of seven new recombinant yellow fever viruses 17D expressing fragments of SIVmac239 Gag, Nef, and Vif in Indian rhesus macaques.

Martins MA, Bonaldo MC, Rudersdorf RA, Piaskowski SM, Rakasz EG, Weisgrau KL, Furlott JR, Eernisse CM, Veloso de Santana MG, Hidalgo B, Friedrich TC, Chiuchiolo MJ, Parks CL, Wilson NA, Allison DB, Galler R, Watkins DI.

PLoS One. 2013;8(1):e54434. doi: 10.1371/journal.pone.0054434. Epub 2013 Jan 15.

12.

Design, construction, and characterization of a multigenic modified vaccinia Ankara candidate vaccine against human immunodeficiency virus type 1 subtype C/B'.

Chen Z, Huang Y, Zhao X, Ba L, Zhang W, Ho DD.

J Acquir Immune Defic Syndr. 2008 Apr 1;47(4):412-21. doi: 10.1097/QAI.0b013e3181651bb2.

PMID:
18209682
13.
14.

Comparison of whole gene and whole virus scrambled antigen approaches for DNA prime and fowlpox virus boost HIV type 1 vaccine regimens in macaques.

Pamungkas J, De Rose R, Iskandriati D, Noviana R, Paramastri Y, Dale CJ, Shoobridge M, Medveczky CJ, Ramshaw IA, Thomson S, Kent SJ.

AIDS Res Hum Retroviruses. 2005 Apr;21(4):292-300.

PMID:
15943571
15.

Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine.

Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, Martin JE, McCluskey MM, Chakrabarti BK, Lamoreaux L, Andrews CA, Gomez PL, Mascola JR, Nabel GJ; Vaccine Research Center 004 Study Team.

J Infect Dis. 2006 Dec 15;194(12):1650-60. Epub 2006 Nov 8.

16.

Head-to-head comparison on the immunogenicity of two HIV/AIDS vaccine candidates based on the attenuated poxvirus strains MVA and NYVAC co-expressing in a single locus the HIV-1BX08 gp120 and HIV-1(IIIB) Gag-Pol-Nef proteins of clade B.

Gómez CE, Nájera JL, Jiménez EP, Jiménez V, Wagner R, Graf M, Frachette MJ, Liljeström P, Pantaleo G, Esteban M.

Vaccine. 2007 Apr 12;25(15):2863-85. Epub 2006 Oct 16.

PMID:
17113200
17.

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.

Nyombayire J, Anzala O, Gazzard B, Karita E, Bergin P, Hayes P, Kopycinski J, Omosa-Manyonyi G, Jackson A, Bizimana J, Farah B, Sayeed E, Parks CL, Inoue M, Hironaka T, Hara H, Shu T, Matano T, Dally L, Barin B, Park H, Gilmour J, Lombardo A, Excler JL, Fast P, Laufer DS, Cox JH; S001 Study Team.

J Infect Dis. 2017 Jan 1;215(1):95-104. doi: 10.1093/infdis/jiw500. Epub 2016 Oct 17.

18.

Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.

Abaitua F, Rodríguez JR, Garzón A, Rodríguez D, Esteban M.

Virus Res. 2006 Mar;116(1-2):11-20. Epub 2005 Oct 7.

PMID:
16214252
19.

Phase 1 evaluation of 3 highly immunogenic prime-boost regimens, including a 12-month reboosting vaccination, for malaria vaccination in Gambian men.

Moorthy VS, Imoukhuede EB, Keating S, Pinder M, Webster D, Skinner MA, Gilbert SC, Walraven G, Hill AV.

J Infect Dis. 2004 Jun 15;189(12):2213-9. Epub 2004 May 24.

PMID:
15181568
20.

Potent specific immune responses induced by prime-boost-boost strategies based on DNA, adenovirus, and Sendai virus vectors expressing gag gene of Chinese HIV-1 subtype B.

Yu S, Feng X, Shu T, Matano T, Hasegawa M, Wang X, Ma H, Li H, Li Z, Zeng Y.

Vaccine. 2008 Nov 11;26(48):6124-31. doi: 10.1016/j.vaccine.2008.09.017. Epub 2008 Sep 22.

PMID:
18812199

Supplemental Content

Support Center